Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/14/2012
Weinberg Cancer Institution at Franklin Square
mi
from
Baltimore, MD
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/14/2012
Weinberg Cancer Institution at Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/14/2012
University of Maryland
mi
from
Baltimore, MD
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/14/2012
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated:  8/14/2012
Pennsylvania Oncology
mi
from
Philadelphia, PA
Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
A Phase 2, Open-Label, Pharmacodynamic Study to Evaluate the Effect of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Subjects With Solid Tumors
Status: Enrolling
Updated: 8/14/2012
Pennsylvania Oncology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated:  8/14/2012
Hartford Hospital Cancer Clinical Research Office
mi
from
Hartford, CT
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated: 8/14/2012
Hartford Hospital Cancer Clinical Research Office
mi
from
Hartford, CT
Click here to add this to my saved trials
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated:  8/14/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated: 8/14/2012
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated:  8/14/2012
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated: 8/14/2012
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated:  8/14/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated: 8/14/2012
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated:  8/14/2012
Virginia Commonwealth University - VCU Massey Cancer Center
mi
from
Richmond, VA
Evaluation of SJG-136 for Cisplatin- Refractory /Resistant Epithelial Ovarian
A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
Status: Enrolling
Updated: 8/14/2012
Virginia Commonwealth University - VCU Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
USC Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Cedar Sinai-Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Cedar Sinai-Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Massachusetts General Hospital
mi
from
Boston, MA
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Oncology Consultants
mi
from
Houston, TX
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Oncology Consultants
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated:  8/15/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer
Phase 1 Study of Anti-HB-EGF Monoclonal Antibody KHK2866 as Monotherapy in Subjects With Advanced Solid Tumors and in Combination With Chemotherapy in Ovarian Cancer
Status: Enrolling
Updated: 8/15/2012
Cancer Therapy and Research Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Sarasota, FL
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Tampa, FL
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Rochester, MN
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Abington, PA
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Abington, PA
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Charleston, SC
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
Dallas, TX
A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 Combination Therapies in Participants With Advanced Cancer (MK-0646-027 AM2)
Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
City of Hope National Medical Center SC-2
mi
from
Duarte, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
City of Hope National Medical Center SC-2
mi
from
Duarte, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
UCLA/ University of California Los Angeles UCLA LeConte Location
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of California San Francisco UCSF (SC)
mi
from
San Francisco, CA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Florida Cancer Specialists Sarasota Office
mi
from
Fort Myers, FL
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Florida Cancer Specialists Sarasota Office
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Rush University Medical Center Rush 3
mi
from
Chicago, IL
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Rush University Medical Center Rush 3
mi
from
Chicago, IL
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Washington University School Of Medicine-Siteman Cancer Ctr SC
mi
from
St. Louis, MO
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Washington University School Of Medicine-Siteman Cancer Ctr SC
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Montefiore Medical Center Montefiore Medical Center (SC)
mi
from
Bronx, NY
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Montefiore Medical Center Montefiore Medical Center (SC)
mi
from
Bronx, NY
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Duke University Medical Center Blue Zone Building
mi
from
Durham, NC
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Duke University Medical Center Blue Zone Building
mi
from
Durham, NC
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Oklahoma Health Sciences Center OUHSC - SC
mi
from
Oklahoma City, OK
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Oklahoma Health Sciences Center OUHSC - SC
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Pittsburgh University of Pittsburgh (SC)
mi
from
Pittsburgh, PA
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Pittsburgh University of Pittsburgh (SC)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Sarah Cannon Research Institute Sarah Cannon Research (SC)
mi
from
Nashville, TN
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Sarah Cannon Research Institute Sarah Cannon Research (SC)
mi
from
Nashville, TN
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Sammons Cancer Center Sammons Cancer Center SC-2
mi
from
Dallas, TX
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Sammons Cancer Center Sammons Cancer Center SC-2
mi
from
Dallas, TX
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
mi
from
San Antonio, TX
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(5)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  8/15/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors
A Phase I, Open-label, Multi-center, Randomized, Crossover Study to Assess the Bioequivalence of 2 Formulations of TKI258, FMI Capsule and FMI Tablet, in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 8/15/2012
University of Wisconsin Univ Wisc
mi
from
Madison, WI
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Glendale, AZ
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Washington,
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Jacksonville, FL
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Roswell, GA
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Roswell, GA
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Grand Rapids, MI
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated:  8/16/2012
GSK Investigational Site
mi
from
Knoxville, TN
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
An Open-label, Randomized, Adaptive Design, Two-period Crossover Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Compared to the Commercial Tablet
Status: Enrolling
Updated: 8/16/2012
GSK Investigational Site
mi
from
Knoxville, TN
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UC San Diego
mi
from
San Diego, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UC San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Miami
mi
from
Miami, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials